Mean pharmacokinetic parameters
| Parameter . | PEG IFN-α-2b weekly dose (μg/kg) . | ||||||
|---|---|---|---|---|---|---|---|
| 0.75 . | 1.5 . | 3.0 . | 4.5 . | 6.0 . | 7.5 . | 9.0 . | |
| Week 1 | |||||||
| n | 3 | 3 | 3 | 3 | 3 | 6 | 6 |
| Cavg (pg/mL) | 184 | 513 | 1 013 | 2 907 | 3 243 | 3 062 | 4 393 |
| AUC(0-168 h) (pg/h/mL) | 30 984 | 86 244 | 170 196 | 488 440 | 544 752 | 514 416 | 738 072 |
| Week 4 | |||||||
| Cavg (pg/mL) | 288 | 725 | 1 338 | 6 931 | 5 548 | 3 006 | 4 592 |
| AUC(0-168 h) (pg/h/mL) | 48 384 | 121 868 | 224 756 | 1 164 476 | 932 124 | 505 022 | 771 410 |
| R | 1.54 | 1.59 | 1.36 | 2.997-150 | 1.65 | 1.26 | 1.19 |
| Parameter . | PEG IFN-α-2b weekly dose (μg/kg) . | ||||||
|---|---|---|---|---|---|---|---|
| 0.75 . | 1.5 . | 3.0 . | 4.5 . | 6.0 . | 7.5 . | 9.0 . | |
| Week 1 | |||||||
| n | 3 | 3 | 3 | 3 | 3 | 6 | 6 |
| Cavg (pg/mL) | 184 | 513 | 1 013 | 2 907 | 3 243 | 3 062 | 4 393 |
| AUC(0-168 h) (pg/h/mL) | 30 984 | 86 244 | 170 196 | 488 440 | 544 752 | 514 416 | 738 072 |
| Week 4 | |||||||
| Cavg (pg/mL) | 288 | 725 | 1 338 | 6 931 | 5 548 | 3 006 | 4 592 |
| AUC(0-168 h) (pg/h/mL) | 48 384 | 121 868 | 224 756 | 1 164 476 | 932 124 | 505 022 | 771 410 |
| R | 1.54 | 1.59 | 1.36 | 2.997-150 | 1.65 | 1.26 | 1.19 |
Including subject 11 (R = 1.49, excluding subject 11).